Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Myeloid Malignancies × olutasidenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 4 Myelodysplastic Syndromes 2 Leukemia, Myelomonocytic, Chronic 2 Targeted Therapy 1 Spinal Cord Neoplasms 1 Oligodendroglioma 1 Myeloproliferative Disorders 1 Myeloid Malignancies 1 Glioma 1 Glioblastoma 1 Diffuse Intrinsic Pontine Glioma 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

venetoclax 1 olutasidenib 1 magrolimab 1 cc-486 1 Mitoxantrone 1 Etoposide 1 Cytarabine 1 Azacitidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06668584 2026-03-04

A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies

M.D. Anderson Cancer Center

Phase 2 Recruiting

Myeloid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡